Health committee From my perspective, if I may draw your attention to the bottom of page 2 from my presentation, it says, “To protect public health by monitoring for the safety and efficacy of our products.” Enough said.
February 5th, 2008Committee meeting
Dr. Colin D'Cunha
Health committee Being aware that the Canadian Medical Association is presenting to you on February 26, and as a member of the CMA, I'll defer to what the association tables before I decide to make further comment.
February 5th, 2008Committee meeting
Dr. Colin D'Cunha
Health committee First and foremost, the assumption is that one receives quality data. Typically when a case is received by a drug safety associate who is a health care professional by background, the quality of the data received is peer-reviewed, medically reviewed, and management reviewed, and
February 5th, 2008Committee meeting
Dr. Colin D'Cunha
Health committee Underreporting is a known phenomenon, not only in drugs but in other events that are subject to surveillance.
February 5th, 2008Committee meeting
Dr. Colin D'Cunha
Health committee The pharmaceutical companies are already required to report everything. It seems to me the challenge is to have the people of Canada, generally, and the health care professionals practising in Canada be stimulated to report, and then from a public policy standpoint, you can use t
February 5th, 2008Committee meeting
Dr. Colin D'Cunha
Health committee If I may respond, I will use a practical example. The load is on the manufacturer to report what the manufacturer is aware of. If the manufacturer is not aware of something, the manufacturer, clearly, can't make up a report and pass it on. That said, we were looking in my depart
February 5th, 2008Committee meeting
Dr. Colin D'Cunha
Health committee To answer the honourable member's question, our perspective is that the government has the role in regulating. Very clearly, manufacturers that have marketed health products in Canada have a legal obligation to report all adverse reactions known to them. The gap that the previous
February 5th, 2008Committee meeting
Dr. Colin D'Cunha
Health committee Good morning, ladies and gentlemen, Madam Chair, and members of the committee. My name is Colin D'Cunha, and I'm joined today by my colleague, Jacqueline Conant. On behalf of the Canadian Generic Pharmaceutical Association and its member companies, I would like to thank you for
February 5th, 2008Committee meeting
Dr. Colin D'Cunha